Anaptys Sees Positive Trial Results for Imsidolimad Psoriasis Treatment
09 Outubro 2023 - 9:43AM
Dow Jones News
By Chris Wack
Anaptys said Monday that it saw positive top-line results from
its global Phase 3 trial evaluating the safety and efficacy of
imsidolimab in patients with generalized pustular psoriasis
flares.
The stock was halted at $19.25 in premarket trading.
The biotechnology company said that investigational imsidolimab
met its primary endpoint in the study population achieving rapid
clearance of pustulation, erythema and scaling after a single dose
of 750mg IV imsidolimab.
Top-line data also demonstrate a favorable safety and
tolerability profile.
All adverse effects reported in imsidolimab-treated patients
were mild or moderate and balanced across imsidolimab-treated
versus placebo patients. No serious or severe adverse effects were
reported in imsidolimab-treated patients.
Anaptys plans to present comprehensive data from the trial in
the second half of 2024. The company anticipates filing a biologics
license application with the U.S. Food and Drug Administration by
the third quarter of 2024.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 09, 2023 08:28 ET (12:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AnaptysBio (NASDAQ:ANAB)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
AnaptysBio (NASDAQ:ANAB)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
